RecruitingPhase 4NCT05735639

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) - a Multi-centre Assessor-blind Randomised-controlled Trial


Sponsor

Imperial College London

Enrollment

3,175 participants

Start Date

Jan 22, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin. They are connected to the bigger deeper veins in the leg (known as deep veins). Because of this, operations to close the varicose veins can increase the chance of a blood clot forming in the deep veins. Blood clots in the deep veins happen in around 1 in 50 people after endovenous operations. A clot in the leg can cause swelling, pain, and other long-term problems. If a clot in the leg breaks off and travels to the lungs, it can cause problems with the lung' ability to move oxygen from the air into the blood and may, in rare cases, be life threatening. Varicose vein procedures may carry a slightly higher risk of blood clot formation, and we are currently unsure if current clot reducing medicines are beneficial in preventing blood clots in people having varicose vein procedures. This study will investigate if it is worthwhile prescribing medicines to reduce blood clots after varicose vein procedures.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Apixaban, a drug called Dabigatran Etexilate, and others for people with varicose veins and venous thromboembolism. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDalteparin Sodium

Low molecular weight heparin

DRUGTinzaparin Sodium

Low molecular weight heparin

DRUGEnoxaparin Sodium

Low molecular weight heparin

DRUGRivaroxaban

Direct oral anticoagulant

DRUGApixaban

Direct oral anticoagulant

DRUGDabigatran Etexilate

Direct oral anticoagulant


Locations(1)

Imperial College Hospital NHS Foundation Trust

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05735639


Related Trials